Medical and Pharmaceutical Cannabinol (CBN) the main ingredient in potential treatments for glaucoma and a rare skin disease InMed Pharmaceuticals has initiated a clinical trial for its epidermolysis bullosa treatment, after regulatory approval in December Nick LabaJanuary 20, 2020